StockDecksAstraZeneca vs Eli Lilly and
AstraZeneca PLC (AZN.L) and Eli Lilly and Company (LLY) · Healthcare
As of 24 October 2026, AstraZeneca has a StockDecks Fundamental Score of +19 (grade B) and Eli Lilly and +26 (grade B+), on a −100 to +100 scale. AstraZeneca rates higher on Valuation; Eli Lilly and rates higher on Financial Health, Profitability and Growth.
| Rating | AZN.L | LLY |
|---|---|---|
| Fundamental Score | +19Grade B | +26Grade B+ |
| Financial Health | -1 | +6 |
| Profitability | +64 | +66 |
| Growth | -3 | +82 |
| Valuation | +17 | -50 |
Both companies are measured against the same Healthcare benchmarks, so their scores compare directly. Scores describe each company as it stands; they are not forecasts or recommendations.
The measures side by side
Each figure is the latest reported value; the number beneath is how it scores on the −100 to +100 scale. A dash means no genuine figure is available. Tap a measure’s name for a plain-English explanation.
Financial Health
| Measure | AZN.L | LLY |
|---|---|---|
| Debt to equity | 0.64×+32 | 1.62×-28 |
| Current ratio | 0.89×-21 | 1.36×+32 |
| Quick ratio | 0.66×-24 | 0.68×-22 |
| FCF / Total debt | 0.16×+2 | 0.2×+13 |
Profitability
| Measure | AZN.L | LLY |
|---|---|---|
| Gross margin | 81.7%+93 | 83.4%+94 |
| Operating margin | 23.5%+59 | 54.2%+98 |
| Net margin | 17%+63 | 33.5%+96 |
| Return on equity | 22%+91 | 102.3%+100 |
| Gross profit / assets | 42.2%+44 | 48.1%+54 |
| Asset turnover | 0.51× | 0.58× |
Growth
| Measure | AZN.L | LLY |
|---|---|---|
| Revenue growth (YoY) | 6.4%+10 | 47.7%+98 |
| Earnings growth (YoY) | 2.5%-9 | 26.2%+76 |
| Earnings growth (Q) | 2.3%-10 | 25.3%+73 |
Valuation
| Measure | AZN.L | LLY |
|---|---|---|
| P/E (trailing) | 26.55×-4 | 42.75×-46 |
| PEG ratio | 1.23×+35 | 1.26×+31 |
| Price/Sales | 3.24×+53 | 14.25×-83 |
| EV/EBITDA | 11.18×+49 | 28.32×-60 |
| FCF yield | 2.6%-32 | 1%-68 |
| Forward P/E | — | 26.97×-21 |
| Price/Book | — | 33.51×-100 |
Key figures
| AZN.L | LLY | |
|---|---|---|
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Market cap | £198.9B | $1.14T |
| Dividend yield | 1.86% | 0.54% |
| Payout ratio | 46.95% | 21.69% |
| Beta | 0.21 | 0.45 |
About the companies
AstraZeneca. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Full AstraZeneca rating
Eli Lilly and. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. Full Eli Lilly and rating
See the live cards
These figures were captured on 24 October 2026. StockDecks shows the current numbers, plus Hype, Analyst Upside, Trend Signals and Insider Track, all free.